Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is entering a new drug approval harvest period with a well-structured pipeline covering ADC (Antibody-Drug Conjugates) and IO (Immuno-Oncology) [3][10]. - The company has multiple oncology product pipelines, including immune therapy, ADC targeted therapy, and oncolytic virus drugs, with several candidates in clinical stages [3][11]. - The company achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development and sales [3][25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, establishing a comprehensive ADC technology platform and has developed multiple ADC products, including PD-1 monoclonal antibody and MRG003 [11][14]. - The pipeline includes six ADC drugs, one oncolytic virus, and one TCE (T-cell Engager) drug in clinical stages, with several candidates entering pivotal trials [14][18]. Unique Features of ADC Candidates - MRG003 (EGFR ADC) has been approved for NPC (Nasopharyngeal Carcinoma) in China, showing superior survival benefits and safety compared to competitors [4][30]. - MRG004A (TF-ADC) is in Phase III trials for pancreatic cancer, while MRG006A (GPC3 ADC) targets the liver cancer market and is expected to enter Phase III trials in 2026 [6][30]. Oncolytic Virus and International Expansion - The company introduced the oncolytic virus therapy CG0070, which is in critical registration trials in China and has shown promising efficacy in the U.S. for bladder cancer [5][30]. - The company has successfully partnered for international expansion with MRG007 (CDH17 ADC) and CTM012 (CD3/4-1BB/DLL3 tri-antibody) [5][30]. Financial Projections and Investment Recommendations - Revenue projections for 2025, 2026, and 2027 are estimated at 880 million, 1.02 billion, and 1.49 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [6][30]. - The company is still in the investment phase for innovative drug development, with projected net profits of -20 million, 10 million, and 280 million yuan for the same years [6][30].

证券日报网讯 1月27日，美康生物（300439）在互动平台回答投资者提问时表示，目前公司国际业务仍 处于起步阶段，主要源于海外市场准入、渠道建设等系统性工作需要培育周期。自2024年公司启动国际 业务体系化建设以来，公司已组建了一支专业化的国际注册与市场拓展团队。2025年，公司在俄罗斯、 土耳其、菲律宾、越南等新兴市场的开拓初见成效。公司将通过持续强化团队能力、加速完成关键市场 产品注册认证，不断提升在国际市场的综合竞争力。 ...

复宏汉霖(02696)发布公告，近日，注射用HLX43(靶向PD-L1抗体偶联药物)(HLX43)联合HLX07(重组抗 EGFR人源化单克隆抗体注射液)(HLX07)及汉斯状® (斯鲁利单抗注射液)(汉斯状®)用于晚期实体瘤治疗 的临床试验申请获国家药品监督管理局(NMPA)批准。公司拟于条件具备后于中国境内开展相关临床试 验。 HLX43的1期临床数据于2025美国临床肿瘤学会(ASCO)年会及2025年世界肺癌大会(WCLC)上先后发 布，在非小细胞肺癌(NSCLC)等实体瘤中展现出良好的安全性及令人鼓舞的初步疗效。HLX07为公司自 主研发的针对EGFR靶点的创新型生物药，计划用于晚期实体瘤治疗。2023年2月，HLX07联合化疗用 于晚期实体瘤治疗的1b/2期临床研究结果显示其安全性及耐受性良好。汉斯状®为公司自主开发的创新 型抗PD-1单抗，其于中国境内(不包括中国港澳台地区，下同)已获批上市的适应症包括联合化疗一线治 疗鳞状非小细胞肺癌(sqNSCLC)、广泛期小细胞肺癌(ES-SCLC)、食管鳞状细胞癌(ESCC) 及非鳞状非小 细胞肺癌(nsqNSCLC)，2025年12月，汉斯状® (斯鲁 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for clinical trial applications of HLX43 in combination with HLX07 and Hanshuo® for the treatment of advanced solid tumors [1][2] Group 1: Clinical Trial Approvals - The clinical trial application for HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hanshuo® has been approved by NMPA [1] - The company plans to conduct the relevant clinical trials within China once conditions are met [1] Group 2: Clinical Data and Product Development - Phase 1 clinical data for HLX43 will be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and the 2025 World Lung Cancer Conference (WCLC), showing promising safety and preliminary efficacy in non-small cell lung cancer (NSCLC) and other solid tumors [2] - HLX07, an innovative biopharmaceutical targeting EGFR, has shown good safety and tolerability in a 1b/2 phase clinical study for advanced solid tumors conducted in February 2023 [2] - Hanshuo®, an innovative anti-PD-1 monoclonal antibody developed by the company, has been approved for multiple indications in mainland China, including first-line treatment for squamous NSCLC and extensive-stage small cell lung cancer [2] - The New Drug Application (NDA) for Hanshuo® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer has been accepted by NMPA and is under priority review [2]

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received approval from the National Medical Products Administration (NMPA) for a clinical trial application involving HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hansizhuang for the treatment of advanced solid tumors [1] Group 1 - The clinical trial will be conducted in China once conditions are met [1]

Core Viewpoint - The company expects to report a net loss attributable to shareholders for the year 2025, with projections ranging from -237 million to -195 million yuan, indicating a reduction in losses compared to the previous year [1] Financial Performance - The anticipated net loss represents a decrease in losses by 84.81 million to 126.81 million yuan compared to the same period last year [1] - The reduction in loss percentage is estimated to be between 26.35% and 39.41% [1]

从单季度表现来看，三生国健2025年前三季度净利润为3.99亿元。据此测算，其第四季度净利润或高达 25.01亿元，是前三季度总和的六倍之多。 对于此次业绩的暴涨，三生国健解释称，这是因为2025年公司与辉瑞达成授权合作，收到对方就707项 目支付的授权许可首付款约28.90亿元所致。 据悉，双方这一合作于去年5月达成，三生国健及关联方三生制药和沈阳三生共同授予辉瑞在除中国大 陆以外区域的独家开发、生产和商业化707项目的权利。 根据协议，辉瑞需支付12.5亿美元不可退换首付款，以及最高可达48亿美元的里程碑付款和两位数百分 比的销售分成，款项分配比例为三生国健30%、沈阳三生70%。值得一提的是，该交易还刷新了国产创 新药对外授权的最高首付款纪录。 股权结构显示，三生国健隶属于港股上市公司三生制药，与沈阳三生均由沈阳医药"大佬"娄竞控制。其 中，三生国健专注于单抗、双抗、多抗及多功能重组蛋白等新技术研究，目前四款后期自免产品均临近 商业化。 此次合作的资产707，则是其基于CLF2专利平台开发的靶向PD-1/VEGF双特异性抗体，具有免疫治疗和 抗血管生成的协同抗肿瘤作用。目前，正在国内开展多项临床研究，单 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣佈，近日，注射用HLX43（靶向PD-L1抗體 偶聯藥物）（「HLX43」）聯合HLX07（重組抗EGFR人源化單克隆抗體注射液） （「HLX07」）及漢斯狀® （斯魯利單抗注射液）（「漢斯狀®」）用於晚期實體瘤治 療的臨床試驗申請獲國家藥品監督管理局（「NMPA」）批准。本公司擬於條件 具備後於中國境內開展相關臨床試驗。 1 B. 關於HLX43、HLX07及漢斯狀® HLX43是由本公司利用許可引進的新型DNA拓撲異構酶I抑制劑小分子毒 素－肽鏈連接符與本公司自主研發的靶向PD-L1的抗體進行偶 ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，生物股份1月27日晚间发布公告称，内蒙古金宇生物控股有限公司持有金宇生物技术股份 有限公司股份约1.25亿股，占公司总股本的11.29%。本次股份质押后，其累计质押公司股份数量为3442 万股，占生物控股持有公司股份数量的27.43%。 ...

报告期内，本集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫 苗曼海欣收入保持持续增长。同时，本集团深入推进降本增效，各项费用得到有效管控;产销协同进一 步优化，毛利率亦有所提升。整体盈利能力显著提升，成功于本报告期实现归属于母公司所有者的净利 润为正。 预计截至2025年12月31日止年度实现归属于母公司所有者的净利润为人民币2450万元到人民币2900万 元，与上年同期相比，将实现扭亏为盈。 预计截至2025年12月31日止年度实现归属于母公司所有者扣除非经常性损益后净亏损为人民币9100万元 到人民币9600万元。 康希诺生物(06185)发布公告，根据中国企业会计准则，预计截至2025年12月31日止年度本集团实现营 业收入人民币10.4亿元到人民币10.8亿元，与上年同期相比，将增加人民币1.94亿元到人民币2.34亿元， 同比增长22.88%到27.61%。 报告期内，随着本集团研发项目的快速推进及国际合作的开展，本集团获得了更多政府专项补助及国际 专项资金的支援，故于本报告期产生较大金额的非经常性收益。 ...